NCT01870739View on ClinicalTrials.gov

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Hypertension
Interventions
DRUG

sacubitril/valsartan (LCZ696)

200 mg tablets

DRUG

olmesartan

OTHER

placebo to sacubitril/valsartan (LCZ696)

placebo

OTHER

placebo to olmesartan

placebo

DRUG

Amlodipine (Optional)

If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen

Trial Locations (4)

4031

Novartis Investigative Site, Basel

10117

Novartis Investigative Site, Berlin

91054

Novartis Investigative Site, Erlangen

G12 8TA

Novartis Investigative Site, Glasgow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY